Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Transcode Therapeutics, Inc.

RNAZ Nasdaq SEC CIK 1829635
Follow Transcode Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$6.8M −57.8% vs same quarter last year
EPS, diluted −$7.17 −39.8% vs same quarter last year
Operating cash flow −$5.4M −28.8% vs same quarter last year
Operating income −$6.8M −60.8% vs same quarter last year
Net income by quarter
−$2.3M
−$5.9M
−$12.1M
−$4.3M
−$4.9M
−$13.4M
−$17.8M
−$6.8M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$34.7M
FY24−$16.8M
FY23−$18.5M
FY22−$17.6M
FY21−$6.8M
FY20−$2.3M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$19.5M
FY24−$13.4M
FY23−$18.1M
FY22−$15.9M
FY21−$5.5M
FY20-
FY19-

News

No stories filed under Transcode Therapeutics yet - coverage appears here as the news feed clusters it.